India's current legal framework leaves genomic data—and AI-driven predictive genomics—insufficiently protected, creating legal uncertainty that could suppress data sharing, investment and innovation unless a dedicated Genetic Data Protection Act, anti‑discrimination law and a national regulator are enacted.

Main Finding

India’s existing legal framework inadequately protects and governs genomic data. Doctrinal and comparative analysis reveals six regulatory gaps that create legal, ethical, and practical risks—especially as India expands genomic research and AI-driven predictive genomics—leading the author to recommend a dedicated Genetic Data Protection Act, a Genetic Non‑Discrimination Act, and a National Genomic Data Regulatory Authority.

Key Points

• Nature of genetic data: inalterable, family‑linked, predictive of future health, and effectively non‑anonymizable, implying heightened legal safeguards are needed.
• Current Indian instruments analyzed:
  • Justice K.S. Puttaswamy (Retd.) v Union of India (2017) (privacy jurisprudence)
  • Digital Personal Data Protection Act (DPDP) 2023 and Rules 2025
  • ICMR National Ethical Guidelines (2017)
• Comparative benchmarks: EU GDPR, US Genetic Information Nondiscrimination Act (GINA), governance models of UK Biobank and Genomics England.
• Six regulatory gaps identified:
• No sui generis “special category” treatment for genetic data (beyond general personal data protections).
• Inadequate informed consent architecture for longitudinal/biobank genomic research (existing consent models are ill‑suited).
• No statutory limits on storage and retention of genomic data.
• Absence of anti‑genetic discrimination legislation (employment, insurance, credit, etc.).
• Structural vulnerabilities in cross‑border genomic data transfer governance (legal uncertainty, weak safeguards).
• No statutory framework addressing AI‑driven predictive genomics (liability, transparency, validation, fairness).
• Recommendations:
  • Enact a dedicated Genetic Data Protection Act with sui generis rules (consent, retention, access controls).
  • Enact a Genetic Non‑Discrimination Act.
  • Establish a National Genomic Data Regulatory Authority to oversee governance, cross‑border transfer, and AI use.
  • Create tailored consent regimes for longitudinal research, statutory retention/archiving rules, and AI‑specific governance (validation, explainability, audit trails).

Data & Methods

• Methodology: doctrinal legal analysis of Indian constitutional and statutory law; comparative legal analysis using EU and US statutes and UK institutional governance as benchmarks.
• Primary legal texts examined: Puttaswamy judgment, DPDP Act (2023), DPDP Rules (2025), ICMR National Ethical Guidelines (2017).
• Comparative materials: GDPR (EU), GINA (US), operational models and governance practices of UK Biobank and Genomics England.
• Analytical approach: identify gaps by contrasting Indian framework with international norms and institutional best practices; derive evidence‑based policy prescriptions grounded in legal doctrine, bioethics, and institutional governance experiences.

Implications for AI Economics

• Data availability and training sets
  • Regulatory gaps (no sui generis protections, unclear consent/retention rules) create legal uncertainty, discouraging data sharing and long‑term biobank development. That can reduce the volume and diversity of genomic datasets available to train AI models, slowing innovation in predictive genomics and precision medicine.
  • Conversely, clearer, trust‑preserving legislation (dedicated Genetic Data Protection Act) could increase public participation in genomic studies, improving dataset quality and market opportunities for AI-driven products.
• Investment and innovation incentives
  • Legal ambiguity and discrimination risk (no anti‑genetic discrimination law) raise policy and reputational risk for startups and investors, likely increasing the cost of capital for genomic AI ventures and biasing funding toward incumbents with compliance capacity.
  • A well‑specified regulatory regime may lower transaction costs and stimulate startup entry, competition, and market dynamism.
• Compliance costs and market structure
  • New statutory rules (storage limits, governance authority, AI validation requirements) will impose compliance costs—favoring larger firms that can absorb them and potentially creating regulatory barriers to smaller innovators unless scaled compliance support is provided.
• Cross‑border data flows and comparative advantage
  • Weak cross‑border governance risks restricting international collaborations and foreign investment, and could prompt data localization or export restrictions that fragment research markets. This affects comparative advantage in global genomics and AI supply chains.
• Labor, insurance, and credit markets
  • Absence of anti‑discrimination protections enables potential genetic discrimination, leading to negative labor market externalities (reduced willingness to test, self‑selection out of certain jobs) and market inefficiencies in insurance and credit pricing. Legal protections would mitigate these distortions and reduce economic harms.
• AI model risk, accountability, and welfare
  • No statutory framework for AI in predictive genomics creates liability and deployment uncertainty: models may be deployed without standards for accuracy, bias mitigation, or clinical validation, increasing the risk of costly errors, false positives/negatives, and downstream economic harm.
  • Regulations requiring validation, transparency, and audits could improve model quality and social welfare but will also affect model development costs and time‑to‑market.
• Policy trade‑offs to anticipate
  • Strong protections that increase trust and participation may boost data throughput and long‑term innovation but raise compliance costs and complexity in the short term.
  • Overly restrictive cross‑border rules or heavy data localization can protect privacy but reduce collaboration gains, raise costs, and shift R&D offshore.
  • A centralized National Genomic Data Regulatory Authority can reduce regulatory fragmentation and lower uncertainty, but its design and enforcement capacity will determine whether it fosters competition or concentrates power.
• Practical recommendations for AI economists and policymakers
  • Model the economic impacts of proposed laws (costs to firms, effects on dataset size/representativeness, welfare gains from reduced discrimination) to design proportionate regulation.
  • Include phased compliance timelines and support mechanisms (sandboxing, standardized consent templates, data stewardship frameworks) to lower barriers for entrants.
  • Require AI‑specific validation/audit standards aligned with international norms to enable cross‑border interoperability and investor confidence.
  • Pair anti‑discrimination rules with enforcement and remedies to prevent market distortions in labor and insurance markets.

If you want, I can draft a short policy brief estimating quantitative effects (e.g., on dataset supply, compliance costs, or investment flows) of different legislative options.